Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression

Cancer Letters

Volumn 244, Issue 1, 2006, Pages 34-41

  Badra, Filitsa A ^a   Karamouzis, Michalis V ^a,b   Ravazoula, Panagiota ^a   Likaki Karatza, Eleni ^a   Tzorakoleftherakis, Evagelos ^a   Koukouras, Dimitrios ^a   Iconomou, Gregorios ^a   Xiros, Nikolaos ^a   Siablis, Dimitrios ^a   Papavassiliou, Athanasios G ^a   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

EGFR; Mammography; Microcalcifications; Non palpable breast carcinomas

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER SCREENING; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PALPATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CALCINOSIS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MAMMOGRAPHY; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR MARKERS, BIOLOGICAL;

EID: 33749235699     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.11.047     Document Type: Article

References (30)

1. Colbert J.A., Kaine E.M., Bigby J.A., Smith D.N., Moore R.H., Rafferty E., et al. The age at which women begin mammographic screening. Cancer 101 (2004) 1850-1859
2. Tabar L., Yen M.F., Vitak B., Chen H.H.T., Smith R.A., and Duffy S.W. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361 (2003) 1405-1410
3. Miettinen O.S., Henschke C.I., Pasmantier M.W., Smith J.P., Libby D.M., and Yankelevitz D.F. Mammographic screening: no reliable supporting evidence?. Lancet 359 (2002) 404-406
4. Ernst M.F., Voogd A.C., Coebergh J.W., and Roukema J.A. Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer 100 (2004) 1337-1444
5. Burstein H.J., Polyak K., Wong J.S., Lester S.C., and Kaelin C.M. Ductal carcinoma in situ of the breast. N. Engl J. Med. 350 (2004) 1430-1441
6. Kerlikowske K., Smith-Bidman R., Ljung B.-M., and Grady D. Evaluation of abnormal mammography results and palpable breast abnormalities. Ann. Intern. Med. 139 (2003) 274-284
7. Mendez A., Cabanillas F., Echenique M., Malekshamran K., Perez I., and Ramos E. Mammographic features and correlation with biopsy findings using 11-gauge stereotactic vacuum-assisted breast biopsy (SVABB). Ann. Oncol. 15 (2004) 450-454
8. Mesurolle B., Ariche-Cohen M., Mignon F., and Goumot P.A. Clustering of breast microcalcifications on digital mammography: which parameters?. Clin. Radiol. 57 (2002) 75-76
9. Roubidoux M.A., Bailey J.E., Wray L.A., and Helvie M.A. Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. Radiology 230 (2004) 42-48
10. Karamouzis M.V., Likaki-Karatza E., Ravazoula P., Badra F.A., Koukouras D., Tzorakoleftherakis E., et al. Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int. J. Cancer 102 (2002) 86-90
11. Atalay G., Cardoso F., Awada A., and Piccart M.J. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann. Oncol. 14 (2003) 1346-1363
12. Suo Z., Risberg B., Kalsson M.G., Willman K., Tierens A., Skovlund E., and Nesland J.M. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. Am. J. Pathol. 196 (2002) 17-25
13. Lodge A.J., Anderson J.J., Gullick W.J., Haugk B., Leonard R.C.F., and Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J. Clin. Pathol. 56 (2003) 300-304
14. Abd El-Rahim D.M., Pinder S.E., Paish C.E., Bell J.A., Rampaul R.S., Blamey R.W., et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J. Cancer 91 (2004) 1532-1542
15. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., and Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int. J. Cancer 106 (2003) 758-765
16. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., and Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200 (2003) 290-297
17. Nishimura S., Takahashi K., Gomi N., Tada K., Makita M., Tada T., et al. What is the predictor for invasion in non-palpable breast cancer with microcalcifications?. Breast Cancer Res. 11 (2004) 49-54
18. Stomper P.C., Geradts J., Edge S.B., and Levine E.G. Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. Am. J. Roentgenol. 181 (2003) 1679-1684
19. Tabar L., Tony Chen H.H., Amy Yen M.F., Tot T., Tung T.H., Chen L.S., et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma. Cancer 101 (2004) 1745-1759
20. Taplin S.H., Ichikawa L., Yood M.U., Manos M.M., Geiger A.M., Weinmann S., et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up?. J. Natl Cancer Inst. 96 (2004) 1518-1527
21. Heimann R., and Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J. Clin. Oncol. 18 (2000) 591-599
22. Ernster V.L., Ballard-Barbash R., Barlow W.E., Zheng Y., Weaver D.L., Cutter G., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J. Natl Cancer Inst. 94 (2002) 1546-1554
23. Karamouzis M.V., Gorgoulis V.G., and Papavassiliou A.G. Transcription factors and neoplasia: vistas in novel drug design. Clin. Cancer Res. 8 (2002) 949-961
24. Srinivasan R., Gillett C.E., Barnes D.M., and Gullick W.J. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Breast Cancer Res. 60 (2000) 1483-1487
25. Stark A., Hulka B.S., Joens S., Novotny D., Thor A.D., Wold L.E., et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J. Clin. Oncol. 18 (2000) 267-274
26. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2 Suppl. 2 (2001) 1-13
27. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl J. Med. 344 (2001) 783-792
28. Arpino G., Green S.J., Allred D.C., Lew D., Martino S., Osborne C.K., and Elledge R.M. HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin. Cancer Res. 10 (2004) 5670-5676
29. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., and Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10 (2004) 331-336
30. Esteva F.J., Hortobagyi G.N., Sahin A.A., Smith T.L., Chin D.M., Liang S.Y., et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol. Oncol. Res. 7 (2001) 171-177